Journal
CHEMICAL & PHARMACEUTICAL BULLETIN
Volume 66, Issue 1, Pages 29-36Publisher
PHARMACEUTICAL SOC JAPAN
DOI: 10.1248/cpb.c17-00380
Keywords
kinase inhibitor; azaindole; hinge binder; fragment-based drug discovery
Ask authors/readers for more resources
The majority of kinase inhibitors have been developed as ATP competitors to interact with a hinge region in ATP binding sites of kinases. 7-Azaindole has been found as an excellent hinge binding motif by making two hydrogen bonds with the kinase hinge region. Vemurafenib, a B-RAF kinase (serine threonine kinase [STK]) inhibitor approved by the U.S. Food and Drug Administration (FDA) for the treatment of melanoma, was created from this simple 7-azaindole fragment by successful use of structure-based drug design techniques. The huge potential of 7-azaindole as a hinge-binding motif has encouraged many researchers to employ it as a kinase privileged fragment. This paper will review recent examples of 7-azaindole-based kinase inhibitors, and discusses their binding interactions with the kinase hinge regions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available